{"id":13233,"date":"2020-12-24T00:07:00","date_gmt":"2020-12-24T00:07:00","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/qnostics-develops-sars-cov-2-test-controls\/"},"modified":"2021-01-14T11:42:32","modified_gmt":"2021-01-14T11:42:32","slug":"qnostics-develops-sars-cov-2-test-controls","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/qnostics-develops-sars-cov-2-test-controls\/","title":{"rendered":"Qnostics develops SARS-CoV-2 test controls"},"content":{"rendered":"
Qnostics, a world leading manufacturer of QC solutions for molecular infectious disease testing, has developed a range of products designed to support the validation, verification and performance monitoring of molecular assays used in the testing of SARS-CoV-2.
\nConveniently combining SARS-CoV-2, Flu A, Flu B and RSV, the new RTX plus control is ideal for use with multiplex assays. A dedicated SARS-CoV-2 control is also available.
\nComprising the full SARS CoV-2 genome, the control range is compatible for use with the majority of commercial and in-house assays. Whole pathogen controls are ideal for full-process validation, monitoring the testing process from extraction to amplification and detection, ensuring the ultimate quality assurance in laboratories.
\nAdditionally, the third-party nature of these controls ensures an independent, unbiased assessment of assay performance in-line with ISO 15189 regulatory requirements. Supplied in a liquid easy to use format, minimal preparation is required. A complementary negative control is also available delivering a complete testing package.
\nFor more information, visit: https:\/\/www.randox.com\/sars-cov-2-molecular-control\/<\/link>\n
\nSupplier:<\/strong> [No title]
\nWebsite:<\/strong> https:\/\/www.randox.com\/sars-cov-2-molecular-control\/<\/a><\/p>\n